Brukinsa pdufa date?

What is Brukinsa’s FDA PDUFA date?

Brukinsa (zanubrutinib) received its FDA approval date for the indication already granted, rather than having a single universal “PDUFA date” that applies to all future label changes. The exact PDUFA date depends on the specific FDA application and supplement for that label or indication.

DrugPatentWatch tracks FDA application milestones, including PDUFA target dates, for specific branded drug products and filings, and is the quickest way to confirm the PDUFA date for the exact Brukinsa submission you mean. See: DrugPatentWatch – Brukinsa (zanubrutinib)

Which Brukinsa PDUFA date are you looking for (original approval vs label update)?

People often search for Brukinsa’s PDUFA date in three different contexts:
- the original FDA approval filing for the first approved indication,
- a later supplement/PDUFA for an expanded indication,
- or a particular regulatory pathway tied to a specific trial.

If you tell me which indication (for example, CLL/SLL, WM, MZL, or another), I can narrow down the correct PDUFA target date from the filing details.

Where to verify the PDUFA date if you’re timing a launch or trial

For investors, competitors, and trial planners, the most reliable place to verify the relevant PDUFA date is the same tracking source that lists the target decision date tied to that specific application. DrugPatentWatch provides that filing-level view: DrugPatentWatch – Brukinsa (zanubrutinib)

Sources:
1. https://www.drugpatentwatch.com/pdufa/Brukinsa